vs

Side-by-side financial comparison of REPLIGEN CORP (RGEN) and TOOTSIE ROLL INDUSTRIES INC (TR). Click either name above to swap in a different company.

TOOTSIE ROLL INDUSTRIES INC is the larger business by last-quarter revenue ($196.3M vs $194.3M, roughly 1.0× REPLIGEN CORP). TOOTSIE ROLL INDUSTRIES INC runs the higher net margin — 14.7% vs 4.3%, a 10.4% gap on every dollar of revenue. On growth, REPLIGEN CORP posted the faster year-over-year revenue change (14.8% vs 1.5%). Over the past eight quarters, TOOTSIE ROLL INDUSTRIES INC's revenue compounded faster (13.2% CAGR vs 12.3%).

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

Tootsie Roll Industries is an American manufacturer of confectionery based in Chicago, Illinois. Its best-known products include the namesake Tootsie Rolls and Tootsie Pops. Tootsie Roll Industries currently markets its brands internationally in Canada, Mexico, and over 75 other countries.

RGEN vs TR — Head-to-Head

Bigger by revenue
TR
TR
1.0× larger
TR
$196.3M
$194.3M
RGEN
Growing faster (revenue YoY)
RGEN
RGEN
+13.3% gap
RGEN
14.8%
1.5%
TR
Higher net margin
TR
TR
10.4% more per $
TR
14.7%
4.3%
RGEN
Faster 2-yr revenue CAGR
TR
TR
Annualised
TR
13.2%
12.3%
RGEN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
RGEN
RGEN
TR
TR
Revenue
$194.3M
$196.3M
Net Profit
$8.3M
$28.8M
Gross Margin
55.7%
35.7%
Operating Margin
8.2%
17.0%
Net Margin
4.3%
14.7%
Revenue YoY
14.8%
1.5%
Net Profit YoY
42.9%
27.9%
EPS (diluted)
$0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RGEN
RGEN
TR
TR
Q1 26
$194.3M
Q4 25
$197.9M
$196.3M
Q3 25
$188.8M
$232.7M
Q2 25
$182.4M
$155.1M
Q1 25
$169.2M
$148.5M
Q4 24
$174.1M
$193.4M
Q3 24
$154.9M
$225.9M
Q2 24
$154.1M
$150.7M
Net Profit
RGEN
RGEN
TR
TR
Q1 26
$8.3M
Q4 25
$13.3M
$28.8M
Q3 25
$14.9M
$35.7M
Q2 25
$14.9M
$17.5M
Q1 25
$5.8M
$18.1M
Q4 24
$-30.3M
$22.5M
Q3 24
$-654.0K
$32.8M
Q2 24
$3.3M
$15.6M
Gross Margin
RGEN
RGEN
TR
TR
Q1 26
55.7%
Q4 25
52.5%
35.7%
Q3 25
53.2%
34.1%
Q2 25
50.0%
36.4%
Q1 25
53.6%
35.3%
Q4 24
26.1%
39.1%
Q3 24
50.0%
34.1%
Q2 24
49.8%
33.5%
Operating Margin
RGEN
RGEN
TR
TR
Q1 26
8.2%
Q4 25
9.0%
17.0%
Q3 25
8.9%
13.9%
Q2 25
7.6%
7.8%
Q1 25
3.9%
15.5%
Q4 24
-17.7%
20.0%
Q3 24
-5.1%
15.6%
Q2 24
1.0%
10.2%
Net Margin
RGEN
RGEN
TR
TR
Q1 26
4.3%
Q4 25
6.7%
14.7%
Q3 25
7.9%
15.3%
Q2 25
8.2%
11.3%
Q1 25
3.4%
12.2%
Q4 24
-17.4%
11.6%
Q3 24
-0.4%
14.5%
Q2 24
2.2%
10.4%
EPS (diluted)
RGEN
RGEN
TR
TR
Q1 26
$0.15
Q4 25
$0.24
Q3 25
$0.26
Q2 25
$0.26
Q1 25
$0.10
Q4 24
$-0.55
Q3 24
$-0.01
Q2 24
$0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RGEN
RGEN
TR
TR
Cash + ST InvestmentsLiquidity on hand
$582.6M
$176.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$941.0M
Total Assets
$2.9B
$1.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RGEN
RGEN
TR
TR
Q1 26
$582.6M
Q4 25
$767.6M
$176.6M
Q3 25
$748.7M
$119.8M
Q2 25
$708.9M
$170.5M
Q1 25
$697.2M
$176.6M
Q4 24
$757.4M
$194.6M
Q3 24
$784.0M
$163.2M
Q2 24
$809.1M
$131.2M
Total Debt
RGEN
RGEN
TR
TR
Q1 26
Q4 25
$542.2M
Q3 25
$537.9M
Q2 25
Q1 25
Q4 24
$525.6M
Q3 24
Q2 24
Stockholders' Equity
RGEN
RGEN
TR
TR
Q1 26
Q4 25
$2.1B
$941.0M
Q3 25
$2.1B
$918.9M
Q2 25
$2.1B
$893.1M
Q1 25
$2.0B
$879.4M
Q4 24
$2.0B
$870.7M
Q3 24
$2.0B
$870.2M
Q2 24
$2.0B
$841.4M
Total Assets
RGEN
RGEN
TR
TR
Q1 26
$2.9B
Q4 25
$2.9B
$1.3B
Q3 25
$2.9B
$1.2B
Q2 25
$2.9B
$1.2B
Q1 25
$2.9B
$1.1B
Q4 24
$2.8B
$1.1B
Q3 24
$2.8B
$1.1B
Q2 24
$2.9B
$1.1B
Debt / Equity
RGEN
RGEN
TR
TR
Q1 26
Q4 25
0.26×
Q3 25
0.26×
Q2 25
Q1 25
Q4 24
0.27×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RGEN
RGEN
TR
TR
Operating Cash FlowLast quarter
$73.3M
Free Cash FlowOCF − Capex
$61.0M
FCF MarginFCF / Revenue
31.1%
Capex IntensityCapex / Revenue
6.3%
Cash ConversionOCF / Net Profit
2.55×
TTM Free Cash FlowTrailing 4 quarters
$96.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RGEN
RGEN
TR
TR
Q1 26
Q4 25
$25.7M
$73.3M
Q3 25
$48.1M
$62.2M
Q2 25
$28.6M
$-8.5M
Q1 25
$15.0M
$3.6M
Q4 24
$39.2M
$68.8M
Q3 24
$49.3M
$61.3M
Q2 24
$42.2M
$-12.6M
Free Cash Flow
RGEN
RGEN
TR
TR
Q1 26
Q4 25
$17.6M
$61.0M
Q3 25
$43.4M
$50.7M
Q2 25
$21.5M
$-16.0M
Q1 25
$11.4M
$750.0K
Q4 24
$33.6M
$64.7M
Q3 24
$42.3M
$55.8M
Q2 24
$37.4M
$-16.6M
FCF Margin
RGEN
RGEN
TR
TR
Q1 26
Q4 25
8.9%
31.1%
Q3 25
23.0%
21.8%
Q2 25
11.8%
-10.3%
Q1 25
6.8%
0.5%
Q4 24
19.3%
33.5%
Q3 24
27.3%
24.7%
Q2 24
24.3%
-11.0%
Capex Intensity
RGEN
RGEN
TR
TR
Q1 26
Q4 25
4.1%
6.3%
Q3 25
2.5%
5.0%
Q2 25
3.9%
4.8%
Q1 25
2.1%
1.9%
Q4 24
3.2%
2.1%
Q3 24
4.5%
2.4%
Q2 24
3.1%
2.6%
Cash Conversion
RGEN
RGEN
TR
TR
Q1 26
Q4 25
1.93×
2.55×
Q3 25
3.23×
1.74×
Q2 25
1.92×
-0.49×
Q1 25
2.57×
0.20×
Q4 24
3.06×
Q3 24
1.87×
Q2 24
12.70×
-0.81×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RGEN
RGEN

Product$194.2M100%
Royalty and other revenue$44.0K0%

TR
TR

Products$194.3M99%
Rental And Royalty$1.9M1%

Related Comparisons